Oncoinvent ASA: New share capital registered

Oncoinvent ASA has registered a share capital change following a fully underwritten rights issue of 260,000,000 new shares to raise gross proceeds of NOK 130 million and the issuance of 31,199,997 underwriting commission shares at NOK 0.50 as fee settlement; after a prior nominal-value reduction the company’s registered share capital is now NOK 223,920,562.50 divided into 447,841,125 shares (NOK 0.50 nominal). The transaction secures committed equity financing while diluting existing shareholders and settles underwriting fees in equity, and comes as Oncoinvent advances its lead radiopharmaceutical candidate Radspherin®—now in a randomized Phase 2 trial in ovarian cancer with encouraging early efficacy signals and no serious safety concerns reported to date.

Analysis

Oncoinvent registered a fully underwritten rights issue of 260,000,000 new shares raising gross proceeds of NOK 130 million and issued 31,199,997 underwriting commission shares at NOK 0.50 as fee settlement; the share capital reduction and these increases were registered with the Norwegian Register of Business Enterprises on 10 December 2025. The company’s registered share capital is now NOK 223,920,562.50 divided into 447,841,125 shares with a nominal value of NOK 0.50 each, meaning approximately 291,199,997 new shares were issued, increasing the outstanding share count from roughly 156.6 million to 447.8 million (more than doubling pre-transaction shares).

The transaction is dilutive to existing shareholders but secures committed equity financing and settles underwriter fees in stock, conserving cash. Oncoinvent’s lead radiopharmaceutical Radspherin® remains in clinical development with one Phase 1 and one Phase 1/2a completed and a randomized Phase 2 ongoing in the US and Europe; the company reports early encouraging efficacy signals and no serious toxicity to date.

The company operates an in-house manufacturing facility in Nydalen, Oslo, which supports clinical supply needs and may reduce outsourcing risk as the Phase 2 progresses. Given the modest market impact score and mixed sentiment, the immediate material effect is financial dilution offset by extended runway to advance Phase 2, making upcoming trial readouts the primary near-term valuation drivers.

Key Decisions for Investors

• Reassess position sizing and valuation models to account for the issuance of ~291.2 million new shares (raising NOK 130m) and the expanded share count to 447.84 million, as existing ownership is materially diluted
• Monitor randomized Phase 2 efficacy and safety readouts as the primary value inflection; consider adding exposure only on demonstrable positive clinical outcomes or clearer regulatory/partnering signals
• Track cash burn and potential for further capital raises despite the NOK 130m proceeds and consider temporary hedging or limiting exposure until post-Phase 2 milestones reduce binary outcome risk